Astrazeneca (AZN) Interest Expenses (2009 - 2026)
Astrazeneca (AZN) posted quarterly Interest Expenses of $435.0 million for Q2 2026, down 0.91% year-over-year from $439.0 million in Q2 2025, and up 198.64% quarter-over-quarter from -$441.0 million in Q1 2026.
Astrazeneca (AZN) Interest Expenses (2009 - 2026) Analysis & Trends
Astrazeneca's Interest Expenses history runs 18 years deep, the most recent figure standing at $435.0 million for Q2 2026.
- In Q2 2026, Interest Expenses fell 0.91% year-over-year to $435.0 million; the TTM figure through Jun 2026 stood at $903.0 million (up 127.98% YoY), while the FY2025 annual figure was $1.7 billion, down 2.76% from the prior year.
- Interest Expenses for Q2 2026 stood at $435.0 million, up from -$441.0 million in the prior quarter.
- The five-year high for Interest Expenses was $2.8 billion in Q4 2025, with the low at -$1.9 billion in Q3 2024.
- The 5-year median for Interest Expenses is -$340.0 million (2022), against an average of -$241.7 million.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses tumbled 818.52% in 2022, then jumped 310.43% in 2025.
- Astrazeneca's Interest Expenses stood at -$608.0 million in 2022, then tumbled by 77.8% to -$1.1 billion in 2023, then declined by 21.46% to -$1.3 billion in 2024, then surged by 310.43% to $2.8 billion in 2025, then slumped by 84.26% to $435.0 million in 2026.
- Business Quant data shows AZN's Interest Expenses at $435.0 million in Q2 2026, -$441.0 million in Q1 2026, and $2.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 435.00 Mn |
| Jun 30, 2026 | 435.00 Mn |
| Mar 31, 2026 | -441.00 Mn |
| Mar 31, 2026 | -441.00 Mn |
| Dec 31, 2025 | 2.76 Bn |
| Dec 31, 2025 | 2.76 Bn |
| Sep 30, 2025 | -1.85 Bn |
| Sep 30, 2025 | -1.85 Bn |
| Jun 30, 2025 | 439.00 Mn |
| Jun 30, 2025 | 439.00 Mn |
| Mar 31, 2025 | -422.00 Mn |
| Mar 31, 2025 | -422.00 Mn |
| Dec 31, 2024 | -1.31 Bn |
| Dec 31, 2024 | -1.31 Bn |
| Sep 30, 2024 | -1.93 Bn |
| Sep 30, 2024 | -1.93 Bn |
| Jun 30, 2024 | 443.00 Mn |
| Jun 30, 2024 | 443.00 Mn |
| Mar 31, 2024 | -341.00 Mn |
| Mar 31, 2024 | -341.00 Mn |